Supreme Court Won't Pause Novartis' Gilenya IP Loss
The U.S. Supreme Court on Thursday denied Novartis' request to stay a Federal Circuit mandate invalidating its patent on the blockbuster multiple sclerosis drug Gilenya, after a generic-drug maker argued that...To view the full article, register now.
Already a subscriber? Click here to view full article